Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Withdrawn): A method for the inhibition of post-operative adhesion formation in a body between tissue surfaces in a body cavity having been subjected to a surgical procedure comprising administering Tranilast, or an analog thereof, directly to said tissue surfaces in said body cavity in amounts and under conditions effective to inhibit formation of adhesions thereon.

Claim 2 (Withdrawn): The method of claim 1 wherein said Tranilast or analog thereof is administered in cooperation with a delivery vehicle suitable for use in the local, non-systemic administration of a therapeutic agent to the body.

Claim 3 (Withdrawn): The method of claim 2 wherein said delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, solutions, compositions, osmotic pumps, fibers, filaments, gels, foams and films.

Claim 4 (Withdrawn): The method of claim 3 wherein said barrier is absorbable.

Claim 5 (Withdrawn): The method of claim 1 wherein said Tranilast is administered in combination with a therapeutic agent, said therapeutic agent administered in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 6 (Withdrawn): The method of claim 5 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

Claim 7 (Withdrawn): The method of claim 1 wherein said Tranilast analog is selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)- carbonylamino)phenyl)formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((ph- enylamino)-carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxypheny- l)-3-(4-((phenylamino)-carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl-)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonyl- amino)phenyl)butanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenylcarb- onylamino) carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen- yl)-3-(4-(2-phenylacetylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethox- yphenyl)-3-(4-(phenoxycarbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamin-o)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophen-yl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamin-o)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophen-yl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylami-no)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylph-enyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylam-ino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-tri-

methoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)ph-enyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carb-onylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((buty- l amino)carbonylamino)phenyl)propanamide and N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide.

Claim 8 (Withdrawn): The method of claim 1 wherein said Tranilast or analog thereof is administered in a single dose.

Claim 9 (Withdrawn): The method of claim 1 wherein said Tranilast or analog thereof is administered by sustained release.

Claim 10 (Withdrawn): The method of claim 1 wherein said Tranilast or analog thereof is administered by burst/sustained release.

Claim 11 (Withdrawn): The method of claim 1 wherein said Tranilast or analog thereof is administered at a level of from about 0.01 milligram per kilogram of the body to about 3,000 milligram per kilogram of the body.

Claim 12 (Withdrawn): The method of claim 1 further comprising administering Tranilast systemically to said body prior to said surgical procedure.

Claim 13 (Withdrawn): The method of claim 1 wherein Tranilast is administered systemically to said body prior to said surgical procedure in amounts and for a time effective to increase inhibition for formation of adhesions in said body when compared to administration of Tranilast directly to said tissue surfaces in said body cavity in said body without said systemic administration.

Claim 14: (Currently Amended) A delivery vehicle suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said vehicle comprising a barrier in a form selected from the group consisting of film, foam, fibers and filaments, and Tranilast or an analog thereof selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)- carbonylamino)phenyl) formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((ph- enylamino)-carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxypheny- l)-3-(4-((phenylamino)-carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl-)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonyl-amino)phenyl)butanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenylcarb-onylamino) carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-(2-phenylacetylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethox-yphenyl)-3-(4-(phenoxycarbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamin-o)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophen-yl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamin-o)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophen-yl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylami-no)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylph-enyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylam-ino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-tri-methoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-

dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)ph-enyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carb-onylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((buty- l amino)carbonylamino)phenyl)propanamide and N-(2-Acetyl-4,5-dimethoxyphen-yl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said Tranilast to said tissue.

Claim 15 (Canceled).

Claim 16 (Currently Amended): The delivery vehicle of claim ~~15~~ 14, wherein said barrier comprises ~~comprising~~ a polymer selected from the group consisting of poloxamers, poly(orthoester)s, ~~poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s,~~ anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(1-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(1-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

Claim 17 (Withdrawn): The delivery vehicle of claim 15 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

Claim 18 (Withdrawn): The delivery vehicle of claim 15 wherein said solution comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

Claim 19 (Withdrawn): The delivery vehicle of claim 15 wherein said solution comprises viscous instillate comprising a carrier selected from the group

consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

Claim 20 (Canceled).

Claim 21 (Currently Amended): The delivery vehicle of claim ~~19~~ 15 wherein said barrier ~~is~~ comprises a material selected from the group consisting of hyaluronic acids, ~~cellulosics derivatives,~~ collagens, ~~polyethylene glycols,~~ pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, ~~polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethyacrylics,~~ aliginates, starches and polypeptides.

Claim 22 (Original): The delivery vehicle of claim 14 further comprising a therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 23 (Original): The delivery vehicle of claim 22 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

Claim 24 (Original): The delivery vehicle of claim 14 wherein said vehicle provides for single dose administration of said Tranilast or analog thereof.

Claim 25 (Original): The delivery vehicle of claim 14 wherein said vehicle provides for sustained release of said Tranilast or analog thereof.

Claim 26 (Canceled).

Claim 27 (Original): The delivery vehicle of claim 14 comprising from about 0.01 milligram Tranilast or analog thereof per kilogram of the body to about 3,000 milligram Tranilast or analog thereof per kilogram of the body.

Claim 28 (Currently Amended): A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising Tranilast or an analog thereof selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)(4-((phenylamino)- carbonylamino)phenyl)formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((ph- enylamino)-carbonylamino) phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxypheny- l)-3-(4-((phenylamino)-carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)-carbonylamino)phenyl-)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonyl- amino)phenyl)butanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenylcarb- onylamino) carbonylamino) phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphen- yl)-3-(4-(2-phenylacetylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethox- yphenyl)-3-(4-(phenoxycarbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-nitrophenyl)amino)carbonylamin- o)phenyl) propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamin-o)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl-)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-

Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)ph-enyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((buty- l amino)carbonylamino)phenyl)propanamide and N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and a carrier in a form selected from the group consisting of film, foam, fibers and filaments, suitable for local, non-systemic administration of said Tranilast or analog thereof.

Claim 29 (Canceled).

Claim 30 (Currently Amended): The composition of claim ~~29~~ 28 wherein said carrier comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, ~~poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s,~~ anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(1-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(1-lactide-co-glyco- lide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

Claim 31 (Original): The composition of claim 28 wherein said composition provides for single dose administration of said Tranilast or analog thereof.

Claim 32 (Original): The composition of claim 28 wherein said composition provides for sustained release of said is Tranilast or analog thereof.

Claim 33 (Canceled).

Claim 34 (Original): The composition of claim 28 comprising from about 0.01 milligram Tranilast or analog thereof per kilogram of the body to about 3,000 milligram Tranilast or analog thereof per kilogram of the body.

Claim 35 (Withdrawn/Currently Amended): The ~~delivery vehicle~~ composition of claim 29 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

Claim 36 (Withdrawn/Currently Amended): The ~~delivery vehicle~~ composition of claim 29 wherein said solution comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

Claim 37 (Withdrawn/Currently Amended): The ~~delivery vehicle~~ composition of claim 29 wherein said solution comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

Claim 38 (Canceled).

Claim 39 (Currently Amended): The ~~delivery vehicle~~ composition of claim ~~38~~ 28 wherein said ~~absorbable barrier~~ carrier ~~is~~ comprises a material selected from the group consisting of hyaluronic acids, ~~cellulosics derivatives,~~ collagens, ~~polyethylene glycols,~~ pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, ~~polyacrylamides, polyvinyl~~

~~pyrrolidones, polyvinyl alcohols, polymethyacrylics,~~ aliginates, starches and polypeptides.

Claim 40 (Currently Amended): The ~~delivery vehicle~~ composition of claim 28 further comprising a therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 41 (Currently Amended): The ~~delivery vehicle~~ composition of claim ~~39~~ 40 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.